查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363072

曲霉菌病治疗市场规模、份额、趋势分析报告：按类型、药物类别、给药途径、给药配销通路、地区、细分市场趋势，2023-2030

Aspergillosis Treatment Market Size, Share & Trends Analysis Report By Type (Allergic, Chronic, Invasive), By Drug Class (Antifungal), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

曲霉病治疗市场的成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球曲霉病治疗市场规模将达到57.9亿美元，2023年至2030年年复合成长率为3.99%。

曲霉菌病感染疾病的罹患率不断上升，特别是在免疫力缺乏的个体中，刺激了对创新治疗方法的需求。医疗技术和药物开发的快速进步导致引入更有针对性和有效的治疗方法，改善患者的治疗效果和治疗效果。意识和诊断能力的提高有助于早期发现和快速开始治疗，进一步增加对各种药物的需求。现有的治疗范例包括除抗生素和皮质类固醇外，也使用唑类抗真菌药物（例如伊曲康唑和伏立康唑）。

F2G、TFF Pharmaceuticals、Scinexis 和 Pulmocide 等知名公司正在推出创新的治疗策略，这些策略有可能重塑侵袭性曲菌病治疗的格局。此类候选药物的成功上市可能对该市场的现有製药领导者构成重大挑战。这项挑战似乎源自于彻底改变既定护理标准并从而为患者提供创新方法的能力。

公司和研究人员目前正在努力评估挑战并确定可能影响研发 (R&D) 和治疗前景的潜在机会。该领域持续配合措施的重点是旨在加强曲霉病应对和管理的创新策略。例如，2022年4月，Palmatrix 宣布恢復其窄谱激酶抑制剂（NSKI）产品组合的全部权利，其中包括 PUR1800。

这项决定是在强生企业创新决定终止与 Palmatrix 先前的授权、开发和商业化协议之后做出的。针对此情况，Pulmatrix 宣布有意继续进行 PUR1800 的开发。该公司计划透过正在进行的临床评估和毒理学研究来继续推进该化合物的发展。这些努力将加强针对慢性阻塞性肺病（COPD）和其他慢性呼吸道疾病急性恶化的计画。

曲霉病治疗市场报告亮点

  • 按类型划分，过敏性细分市场在 2022 年占据最大的销售份额。这种增长是由于患病疾病症状轻微，特别是过敏性支气管肺曲菌病（ABPA）等疾病，它影响气喘和囊性纤维化患者。
  • 依药品类别划分，2022年抗真菌药物占最大销售份额。这种增长是由于它对曲霉菌感染的有效性及其作为主要治疗选择的广泛使用。
  • 根据给药途径，口服药物领域在 2022 年占据最大的收益占有率。这种增长归因于其便利性和患者友好的给药方法，使其成为医疗保健提供者和患者的首选。
  • 从配销通路来看，医院药房细分市场占据主导地位，2022年份额为47.59%。这一增长归因于以医院为基础的配销通路在曲霉菌病治疗的有效提供和可及性方面发挥的关键作用。
  • 2022年，北美将主导市场。这一优势源于强调该地区先进的医疗基础设施、充满活力的研发 (R&D) 努力以及尖端医疗技术的多种要素的综合作用。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场趋势及展望
  • 市场动态
    • 曲霉菌病患病患病增加
    • 医学研究进展
    • 改善识别和诊断
  • 市场抑制因素分析
    • 治疗选择有限
    • 昂贵的治疗费用
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第4章曲霉病治疗市场：按类型細項分析

  • 曲霉病治疗：2022 年和 2030 年市场占有率分析
  • 过敏性曲菌病
  • 慢性曲菌病
  • 侵袭性曲菌病

第5章曲霉病治疗市场：依药物分类分析

  • 曲霉病治疗：2022 年和 2030 年市场占有率分析
  • 抗真菌药物
  • 其他的

第6章曲霉菌病治疗市场：依给药途径細項分析

  • 曲霉病治疗：2022 年和 2030 年市场占有率分析
  • 口腔医学
  • 软膏
  • 粉末
  • 其他的

第7章曲霉病治疗市场：依配销通路細項分析

  • 曲霉病治疗：2022 年和 2030 年市场占有率分析
  • 医院药房
  • 零售药房
  • 其他的

第8章区域业务分析

  • 2022 年及 2030 年曲霉菌病治疗市场占有率（按地区）
  • 北美洲
    • 北方曲菌病治疗市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲曲霉菌病治疗市场，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区曲菌病治疗市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲曲霉菌病治疗市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • SWOT分析
    • MEA 曲菌病治疗市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场占有率分析
  • 公司简介/名单
    • Pfizer, Inc
    • Merck &Co
    • F2G
    • Novartis AG;
    • Astellas Pharma Inc
    • Bayer AG
    • Mayne Pharma Group Limited
    • PULMATRiX
Product Code: GVR-4-68040-123-2

Aspergillosis Treatment Market Growth & Trends:

The global aspergillosis treatment market size is expected to reach USD 5.79 billion by 2030, registering a CAGR of 3.99% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The rising incidence of aspergillosis infections, particularly among immunocompromised individuals, has spurred the demand for innovative treatment approaches. Rapid advancements in medical technology and drug development have led to the introduction of more targeted and effective therapies, enhancing patient outcomes and treatment efficacy. Improved awareness and diagnostic capabilities contribute to early detection and prompt treatment initiation, further increasing the demand for various drugs. The existing treatment paradigm predominantly relies on the utilization of conventional antifungal drugs such as azoles (such as Itraconazole and voriconazole), in addition to antibiotics and corticosteroids.

Several prominent companies such as F2G, TFF Pharmaceuticals, Scynexis, and Pulmocide are in the process of introducing innovative therapeutic strategies that hold the potential to reshape the landscape of Invasive Aspergillosis treatment. The successful launch of such candidates could pose a substantial challenge to the established pharmaceutical leaders in the market. This challenge would arise from their capacity to revolutionize the established standard of care, thereby offering a transformative approach for patients.

Companies and researchers are currently engaged in evaluating challenges and identifying potential opportunities that could impact the research and development (R&D) and treatment landscape. The ongoing efforts in this field are centered around innovative strategies aimed at addressing and enhancing the management of Aspergillosis. For instance, in April 2022, Pulmatrix announced the restoration of complete rights to its portfolio of narrow-spectrum kinase inhibitors (NSKIs), which includes PUR1800.

This decision came about after the determination by Johnson & Johnson's Enterprise Innovation to terminate the licensing, development, and commercialization agreement previously established with Pulmatrix. In response, Pulmatrix has outlined its intention to proceed with the advancement of PUR1800. The company plans to continue the progression of this compound by conducting continuous clinical assessments and toxicology studies. These endeavors are undertaken to bolster programs focused on acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD) as well as other chronic respiratory conditions.

Aspergillosis Treatment Market Report Highlights:

  • Based on type, the allergic segment held the largest revenue share in 2022, the growth can be attributed to higher prevalence and milder disease presentation, particularly in conditions such as allergic bronchopulmonary aspergillosis (ABPA) affecting asthma and cystic fibrosis patients
  • Based on drug class, the antifungal drug segment held the largest revenue share in 2022, the growth can be attributed to their effectiveness in combating aspergillosis infections and their wide usage as a primary treatment option
  • Based on route of administration, the oral drugs segment held the largest revenue share in 2022. This growth is due to its convenience and patient-friendly administration, making it a preferred choice for both healthcare providers and patients
  • Based on distribution channel, the hospital pharmacy segment dominated the market with a share of 47.59% in 2022. This growth is due to the pivotal role that hospital-based distribution channels play in the effective delivery and accessibility of treatments for aspergillosis
  • North America dominated the market in 2022. This dominance can be attributed to a confluence of factors that underscore the region's advanced healthcare infrastructure, dynamic research and development (R&D) endeavors, access to cutting-edge medical technologies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Drug Class
      • 1.1.1.3. Route of Administration
      • 1.1.1.4. Distribution Channel
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing Prevalence of Aspergillosis
    • 3.4.2. Advancements in Medical Research
    • 3.4.3. Awareness and Diagnosis Improvement
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Treatment Options
    • 3.5.2. High Treatment Costs
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Aspergillosis Treatment Market: By Type Segment Analysis

  • 4.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 4.2. Allergic Aspergillosis
    • 4.2.1. Allergic Aspergillosis Market, 2018 - 2030 (USD Million)
  • 4.3. Chronic Aspergillosis
    • 4.3.1. Chronic Aspergillosis Market, 2018 - 2030 (USD Million)
  • 4.4. Invasive Aspergillosis
    • 4.4.1. Invasive Aspergillosis Market, 2018 - 2030 (USD Million)

Chapter 5. Aspergillosis Treatment Market: Drug Class Segment Analysis

  • 5.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 5.2. Antifungal Drugs
    • 5.2.1. Antifungal Drugs Market, 2018 - 2030 (USD Million)
      • 5.2.1.1. Azoles
      • 5.2.1.2. Echinocandins
      • 5.2.1.3. Polyenes
      • 5.2.1.4. Allylamines
      • 5.2.1.5. Others
  • 5.3. Others
    • 5.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Aspergillosis Treatment Market: Route of Administration Segment Analysis

  • 6.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 6.2. Oral Drugs
    • 6.2.1. Oral Drugs Market, 2018 - 2030 (USD Million)
  • 6.3. Ointments
    • 6.3.1. Ointments Market, 2018 - 2030 (USD Million)
  • 6.4. Powders
    • 6.4.1. Powders Market, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Aspergillosis Treatment Market: By Distribution Channel Segment Analysis

  • 7.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 7.2. Hospital Pharmacy
    • 7.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.3. Retail Pharmacy
    • 7.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Aspergillosis Treatment Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Brazil Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Mexico Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. South Africa Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Saudi Arabia Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. UAE Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Kuwait Aspergillosis Treatment Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. Pfizer, Inc
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Merck & Co
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. F2G
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Novartis AG;
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Astellas Pharma Inc
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bayer AG
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Mayne Pharma Group Limited
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. PULMATRiX
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 3 Global aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 Global aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global aspergillosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 North America aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 12 U.S. aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 13 U.S. aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 U.S. aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Canada aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 25 UK aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 26 UK aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 UK aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 30 Germany aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Germany aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 34 France aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 France aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Italy aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 38 Italy aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Italy aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Italy aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Spain aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 42 Spain aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Spain aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Spain aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Denmark aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 50 Sweden aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Sweden aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 54 Norway aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Norway aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63 Japan aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 64 Japan aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 Japan aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Japan aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 China aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 China aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 China aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 China aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 India aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 72 India aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 India aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74 India aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Australia aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 76 Australia aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Australia aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Australia aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Thailand aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 80 Thailand aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 Thailand aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Thailand aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Korea aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Korea aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Korea aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Latin America aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 88 Latin America aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Latin America aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America aspergillosis treatment market, by country, 2018 - 2030 (USD Million
  • Table 92 Brazil aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 93 Brazil aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Brazil aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Brazil aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Mexico aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 97 Mexico aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 98 Mexico aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99 Mexico aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 101 Argentina aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 102 Argentina aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 Argentina aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 Middle East & Africa aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 110 South Africa aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 111 South Africa aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 112 South Africa aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 113 South Africa aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 118 UAE aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 119 UAE aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 120 UAE aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 121 UAE aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 123 Kuwait aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 124 Kuwait aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 125 Kuwait aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Aspergillosis treatment market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market Trends & outlook
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global aspergillosis treatment market: By Type movement analysis
  • Fig. 16 Global aspergillosis treatment market, for allergic aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 17 Global aspergillosis treatment market, for chronic aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 18 Global aspergillosis treatment market, for invasive aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 19 Global aspergillosis treatment market: Drug Class movement analysis
  • Fig. 20 Global aspergillosis treatment market, for antifungal drugs (Azoles, Echinocandins, Polyenes, Allylamines, Others) 2018 - 2030 (USD Million)
  • Fig. 21 Global aspergillosis treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 22 Global aspergillosis treatment market: Route of Administration movement analysis
  • Fig. 23 Global aspergillosis treatment market, for oral drugs, 2018 - 2030 (USD Million)
  • Fig. 24 Global aspergillosis treatment market, for ointments, 2018 - 2030 (USD Million)
  • Fig. 25 Global aspergillosis treatment market, for powders, 2018 - 2030 (USD Million)
  • Fig. 26 Global aspergillosis treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 27 Global aspergillosis treatment market: Distribution Chanel movement analysis
  • Fig. 28 Global aspergillosis treatment market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 29 Global aspergillosis treatment market, for retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global aspergillosis treatment market, for other pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional outlook, 2022 & 2030
  • Fig. 33 Global aspergillosis treatment market: Region movement analysis
  • Fig. 34 North America aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 UK aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 China aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 India aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait aspergillosis treatment market, 2018 - 2030 (USD Million)